EUVIMEDEUVIMED entdecken
Crossref

Alleviation of renal ischemia-reperfusion injury by quercetin, kaempferol, and luteolin in Shiwei Hezi pill (SHP): Network pharmacology and molecular docking analysis of a traditional Tibetan herbal agent

Drolma Gomchok, Hui Yang, Tana Wuren

Int. Journal of Clinical Pharmacology and Therapeutics · 2025

DOI: 10.5414/cp204701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2025. Verfasst von Drolma Gomchok und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Reperfusion Injury, Kaempferols, Quercetin, Luteolin. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The aim of the study was to utilize a systematic network pharmacology approach to explore the active components, targets, and pathways associated with the efficacy of Shiwei Hezi pill (SHP) in treating renal ischemia-reperfusion injury (RIRI). MATERIALS AND METHODS: We utilized online databases to identify common targets of SHP and RIRI. Functional annotation of genes using the Gene Ontology (GO) and enrichment analysis of pathways using the Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed using bioinformatics websites. Cytoscape was utilized to generate and visualize protein-protein interaction (PPI) networks. We employed specialist software to conduct molecular docking analysis on crucial constituents and targets in order to validate the interaction patterns between core ingredients and essential targets. RESULTS: We screened 54 ingredients with good bioavailability in SHP and identified 204 shared targets between SHP and RIRI. Our data suggests that SHP may primarily target TNF, IL6, GAPDH, MMP9, PTGS2, and MMP6 in the therapeutic management of RIRI. The GO enrichment and KEGG pathway enrichment show that the mechanism of SHP treatment for RIRI involves multiple biological processes and signaling pathways. The molecular docking indicates that the three most potent active components of SHP (quercetin, kaempferol, and luteolin) have a strong likelihood of binding to TNF, IL6, GAPDH, MMP9, and PTGS2 with a high degree of affinity. CONCLUSION: This is the first exploration of the potential mechanism of Tibetan medicine formula SHP in treating RIRI using network pharmacology. Our research indicates that the various components of SHP could act on multiple targets and signaling pathways associated with RIRI. The findings in this study provide a theoretical basis and a novel method for the clinical therapy of RIRI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reperfusion InjuryKaempferolsQuercetinLuteolinDrugs, Chinese HerbalKidneyMolecular Docking SimulationNetwork PharmacologyProtein Interaction MapsHumansSignal TransductionComputational BiologyAnimals

Substanzen

KaempferolskaempferolQuercetinLuteolinDrugs, Chinese Herbal

Zitieren

APA

Gomchok, D., Yang, H., & Wuren, T. (2025). Alleviation of renal ischemia-reperfusion injury by quercetin, kaempferol, and luteolin in Shiwei Hezi pill (SHP): Network pharmacology and molecular docking analysis of a traditional Tibetan herbal agent. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204701

Vancouver

Gomchok D, Yang H, Wuren T. Alleviation of renal ischemia-reperfusion injury by quercetin, kaempferol, and luteolin in Shiwei Hezi pill (SHP): Network pharmacology and molecular docking analysis of a traditional Tibetan herbal agent. Int. Journal of Clinical Pharmacology and Therapeutics. 2025. doi:10.5414/cp204701

BibTeX
@article{Gomchok2025,
  author = {Gomchok, Drolma and Yang, Hui and Wuren, Tana},
  title = {Alleviation of renal ischemia-reperfusion injury by quercetin, kaempferol, and luteolin in Shiwei Hezi pill (SHP): Network pharmacology and molecular docking analysis of a traditional Tibetan herbal agent},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2025},
  doi = {10.5414/cp204701}
}
Kostenlos starten →